强化利尿联合延迟显像对68Ga-PSMA-11 PET/CT病灶可见性与示踪剂摄取的影响
回顾性比较旧方案(仅标准利尿水化后2.5小时延迟显像)与新方案(延迟显像前30分钟追加水化与呋塞米)对68Ga-PSMA-11 PET/CT中膀胱活性、病灶摄取及对比度的影响。新方案显著降低延迟显像时膀胱活性比值,避免旧方案中因膀胱活性增高而掩盖局部复发灶的情况。推荐在延迟显像前追加利尿与水化以提高局部复发病灶的可见性与诊断确定性。
要点
- 延迟显像前追加水化与呋塞米可显著降低膀胱活性,避免掩盖局部复发灶。
- 旧方案中4/76(5.2%)患者病灶在2.5小时延迟显像因膀胱活性增高而不可见。
- 新方案中2/56(3.6%)患者病灶仅延迟显像可见,2例病灶判别更佳。
核心结论
- 利尿与水化联合可提高标准68Ga-PSMA-11 PET/CT对局部复发前列腺癌的显示与检出,但其效应不足以延续至延迟显像。
- 推荐在延迟显像前追加利尿与水化以改善局部复发病灶的可见性、检出率与诊断确定性。
研究设计与样本
- 回顾性研究比较旧方案与新方案两组接受68Ga-PSMA-11 PET/CT并因不确定病灶或低PSA行延迟显像的患者。
- 共纳入132例患者,旧方案76例,新方案56例。
- 旧方案:注射后90分钟显像,注射后30分钟开始口服水化1 L,注射后1小时静脉给予呋塞米20 mg,注射后2.5小时无额外准备行延迟显像。
- 新方案:在旧方案基础上,于延迟显像前30分钟追加口服水化0.5 L并静脉给予呋塞米10 mg。
主要发现
- 旧方案延迟显像膀胱活性比值(2.5小时/1.5小时)为2.33 ± 1.17,新方案为1.37 ± 0.50,P < 0.0001。
- 两组2.5小时较1.5小时肿瘤SUVmax与对比度均增高(旧方案P < 0.0001;新方案P = 0.02)。
- 旧方案膀胱活性增高导致病灶-膀胱对比度下降,新方案未见此现象。
- 两方案延迟显像肿瘤-背景比值均增高,但新方案增幅显著较低。
- 旧方案中4/76(5.2%)患者病灶在1.5小时可见而2.5小时因膀胱活性增高不可见;新方案中2/56(3.6%)患者病灶仅延迟显像可见,2例病灶判别更佳。
临床怎么用
- 对因不确定病灶或低PSA行68Ga-PSMA-11 PET/CT延迟显像的患者,建议在延迟显像前追加水化与呋塞米以降低膀胱活性。
- 追加利尿水化有助于提高局部复发病灶的可见性与诊断确定性,减少因膀胱活性增高导致的漏诊。
局限性
- 回顾性研究设计。
- 样本量有限(共132例)。
- 比较的是两个不同方案组,非随机对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Renal excretion of some prostate-specific membrane antigen (PSMA) ligands and consequently increased bladder activity can obscure locally relapsing prostate cancer lesions in PSMA PET/CT. Furthermore, additional late imaging in PSMA PET/CT provides a useful method to clarify uncertain findings. The aim of this retrospective study was to investigate a modified imaging protocol combining late additional imaging with hydration and forced diuresis in individuals undergoing additional late scanning for uncertain lesions or low prostate-specific antigen. Methods: We compared an older protocol with a newer one. In the old protocol, patients undergoing 68Ga-PSMA-11 PET/CT were examined at 90 min after injection, with 1 L of oral hydration beginning at 30 min after injection and 20 mg of furosemide given intravenously at 1 h after injection, followed by additional late imaging at 2.5 h after injection without further preparation. In the new protocol, a second group received the same procedure as before, with an additional 0.5 L of oral hydration and 10 mg of furosemide intravenously 30 min before the late imaging. We examined 132 patients (76 with the old protocol and 56 with the new one) with respect to urinary bladder activity (SUVmean), prostate cancer lesion uptake (SUVmax), and lesion contrast (ratio of tumor SUVmax to bladder SUVmean for local relapses and ratio of tumor SUVmax to gluteal-muscle SUVmean for nonlocal prostate cancer lesions). Results: Bladder activity was significantly greater for the old protocol in the late scans than for the new protocol (ratio of bladder activity at 2.5 h to bladder activity at 1.5 h, 2.33 ± 1.17 vs. 1.37 ± 0.50, P < 0.0001). Increased tumor SUVmax and contrast were seen at 2.5 h compared with 1.5 h (P < 0.0001 for old protocol; P = 0.02 for new protocol). Increased bladder activity for the old protocol resulted in decreased lesion-to-bladder contrast, which was not the case for the new protocol. Tumor-to-background ratios increased at late imaging for both protocols, but the increase was significantly lower for the new protocol. For the old protocol, comparing the 1.5-h to the 2.5-h acquisitions, 4 lesions in 4 patients (4/76 = 5.2% of the cohort) were visible at the postdiuresis 1.5-h acquisition but not at 2.5 h, having been obscured as a result of the higher bladder activity. In the new protocol, 2 of 56 (3.6%) patients had lesions visible only at late imaging, and 2 patients had lesions that could be better discriminated at late imaging. Conclusion: Although the combination of diuretics and hydration can be a useful method to increase the visualization and detectability of locally recurrent prostate cancer in standard 68Ga-PSMA-11 PET/CT, their effects do not sufficiently continue into additional late imaging. Additional diuresis and hydration are recommended to improve the visibility, detection, and diagnostic certainty of local recurrences.
引用
- Alberts I, Niklas-Hünermund J, Sachpekidis C, et al. Combination of Forced Diuresis with Additional Late Imaging in 68Ga-PSMA-11 PET/CT: Effects on Lesion Visibility and Radiotracer Uptake. J Nucl Med. 2021. PMID: 33547214. doi:10.2967/jnumed.120.257741
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。